Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harmony Biosciences Holdings (HRMY – Research Report), Decibel Cannabis Company (DBCCF – Research Report) and Avid Bioservices (CDMO – Research Report).
Harmony Biosciences Holdings (HRMY)
In a report released today, Corinne Johnson from Goldman Sachs maintained a Sell rating on Harmony Biosciences Holdings. The company’s shares closed last Monday at $29.25.
According to TipRanks.com, Johnson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Harmony Biosciences Holdings with a $42.00 average price target.
See today’s best-performing stocks on TipRanks >>
Decibel Cannabis Company (DBCCF)
In a report released today, Andrew Semple from Echelon Wealth Partners maintained a Buy rating on Decibel Cannabis Company, with a price target of C$0.30. The company’s shares closed last Monday at $0.09.
According to TipRanks.com, Semple is a 1-star analyst with an average return of
Decibel Cannabis Company has an analyst consensus of Moderate Buy, with a price target consensus of $0.24, which is a 157.2% upside from current levels. In a report released today, Haywood also reiterated a Buy rating on the stock with a C$0.35 price target.
Avid Bioservices (CDMO)
Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Avid Bioservices today and set a price target of $16.00. The company’s shares closed last Monday at $7.56.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Avid Bioservices is a Strong Buy with an average price target of $12.00, a 61.9% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HRMY:
- Harmony Biosciences Unveils Investor Presentation with Future Insights
- Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
- Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
- Harmony Biosciences signs exclusive licensing agreement for sleeping disorders
- Harmony Biosciences begins Phase 3 registrational study of pitolisant in PWS
